AIMS65 score and shock index in predicting mortality in patients with acute upper gastrointestinal bleeding

Fatih Doğanay,¹ Erdal Yılmaz²

¹ Specialist of Emergency Medicine, Department of Emergency Medicine, Edremit State Hospital, Balıkesir
² Specialist of Emergency Medicine, Department of Emergency Medicine, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey

Abstract

Aim: The aim of the study was to investigate the effectiveness of the shock index (SI) and the AIMS65 score in predicting mortality in patients with upper gastrointestinal bleeding (UGIB) who presented to the emergency department (ED).

Material and Methods: The files of all patients with a diagnosis of UGIB over the age of 18 who visited ED during the study period were scanned from the hospital archives, taking into account the International Classification of Diseases (ICD) codes. Receiver operating characteristic (ROC) analysis, the area under the curve (AUC) and Youden Index J (YIJ) were performed to analyze the performance of AIMS65 and SI in predicting in-hospital mortality.

Results: This retrospective observational study was conducted using data from 594 patients. The median age of the study population was 68 (81-54). Sensitivity, specificity, PPV, NPV, AUC and YIJ values for the AIMS65 score were calculated as 100%, 64.21%, 17.60%, 100%, 0.917, 0.642, respectively (P < 0.001). The same values for the shock index were calculated as 71.43%, 88.80%, 32.8%, 97.6%, 0.807, and 0.602, respectively (P < 0.001).

Discussion: In this study, the AIMS65 score was found to be more successful than SI in predicting mortality in UGIB patients. We suggest that the AIMS65 score, which is an easily calculated score in emergency departments, should be used to predict mortality in UGIB patients.

Keywords

Gastrointestinal diseases; Gastrointestinal hemorrhage; Risk scores; Shock.
Introduction
Acute upper gastrointestinal bleeding (UGIB) which originates proximal to the ligament of Treitz is a serious disease that can result in mortality [1]. This disease, which affects 48-160 out of 100,000 adults per year, can lead to poor outcomes such as recurrent UGIB (reach to 26%) and death (2%-12%) [2, 3]. Therefore, early identification of critically ill patients who will require early invasive procedures is important. International guidelines recommend the use of risk scores at the time of the first admission to the emergency department (ED) of UGIB patients [4, 5]. However, most of these scores include endoscopic data [6-8]. These scores are useless for emergency departments, given that endoscopy is difficult to access in many emergency departments. In 2011, Saltzman JR et al. reported a simple score to assess the prognosis of patients with UGIB. This score has five variables that do not include endoscopic data: age, systolic blood pressure (SBP), altered level of consciousness, international normalized ratio (INR), and albumin. The patient will receive one point for the presence of each variable. As a result, the mortality rate is 0.3% for 0 points, 1.2% for 1 point, 5.3% for 2 points, 10.3% for 3 points, 16.5% for 4 points and 24.5% for 5 points. Those who score zero or one on the AIMS65 score are classified as low-risk in terms of in-hospital mortality risk, while those with a score of two to five are classified as high-risk. In the same study, the AIMS65 score was reported to be beneficial in reducing the length and cost of hospital stay as well as in-hospital mortality in patients with UGIB [9].

The shock index (SI) is a practical risk predictor, calculated as the ratio of heart rate (HR) to SBP. SI has been shown to increase with acute hypovolemia and left ventricular dysfunction [10]. The UK National Confidential Inquiry into Patient Outcome and Death (NCEPOD) report, published in 2015, recommended the use of the SI to identify patients with UGIB at high risk of poor outcome and the possible need for early intervention (available at: http://www.ncepod.org.uk/2015gh.html).

The aim of this study was to investigate the efficacy of SI and AIMS65 score in predicting mortality risk in patients with the diagnosis of UGIB.

Material and Methods
This retrospective observational study was carried out in the ED of a tertiary care hospital between January 1, 2020, and June 1, 2020. The institutional review board approved the analysis of data [9]. After applying the exclusion criteria, this study was conducted using data from 394 patients. The number of patients in the groups was 366 for the survivors group and 28 for the non-survivors group. Among the patients included in the study, 147 were females and 247 were males. There was a statistically significant difference in favor of males between the groups in terms of genders (Table 1).

The median age of the study population was 68 (81-54) years, and the median age of the groups was calculated as 67 (53-80.25) years for the survivors group and 74 (67.5-84.75) years for the non-survivors group. A statistically significant difference was found between the groups in terms of age (Table 2).

When the effects of chronic diseases on mortality in UGIB patients were analyzed, there was a statistically significant difference in terms of mortality between the survivors and non-survivors groups for liver disease (LD), ischemic heart disease (IHD), and congestive heart failure (CHF). (Table 1).

When the effects of vital parameters on mortality were analyzed, there was a statistically significant difference between the groups for SBP, DBP, HR and spO2 (Table 2). When the effects of symptoms on mortality were analyzed, there was a statistically significant difference between the groups for hematochezia, hematemesis, syncope and unconsciousness, while there was no statistically significant difference for melena (Table 2).

When the effectiveness of laboratory parameters in relation to mortality was analyzed, there was a significant difference between the groups for hemoglobin, urea, creatinine, INR, and albumin, while there was no significant difference between the groups for platelet count (Table 2).

The accuracy of the AIMS65 score and SI in predicting in-hospital mortality was analyzed by ROC analysis. Sensitivity, specificity, PPV, NPV, AUC and YJI values for the AIMS65 score
were calculated as 100%, 64.21%, 17.60%, 100%, 0.917, 0.642, respectively (P < 0.001) (Table 3). The same values for the shock index were calculated as 71.43%, 88.80%, 32.8%, 97.6%, 0.807, and 0.602, respectively (P < 0.001) (Table 3). The ideal threshold values for predicting in-hospital mortality in UGIB patients were calculated as “≥2” for the AIMS65 score and “>0.967” for the shock index (Table 3). When the ROC curves of the AIMS65 score and the shock index were compared, it was seen that there was a statistically significant difference between the two curves (p=0.0289).

### Table 1. Gender, symptoms and comorbidity descriptives of the study population

| Variables | Category | Survivors (n=366) | Non-Survivors (n=28) | Sig. |
|-----------|----------|-----------------|-------------------|------|
| Gender    | Male     | 235 (95.10%)    | 12 (4.90%)        | 0.024|
|           | Female   | 131 (89.10%)    | 16 (10.90%)       |      |
| Symptoms  |          |                 |                   |      |
| Melena    | No       | 90 (90.90%)     | 9 (9.10%)         | 0.375|
|           | Yes      | 276 (96.25%)    | 14 (3.75%)        |      |
| Hematochezia | No    | 316 (93.40%)    | 23 (6.60%)        | 0.008|
|           | Yes      | 50 (80.00%)     | 12 (20.00%)       |      |
| Hematemesis | No     | 291 (95.70%)    | 14 (4.30%)        | >0.001|
|           | Yes      | 74 (83.10%)     | 15 (16.90%)       |      |
| Syncope   | No       | 345 (95.00%)    | 18 (5.00%)        | >0.001|
|           | Yes      | 23 (69.70%)     | 10 (30.30%)       |      |
| Unconsciousness | Altered | 33 (88.80%) | 4 (11.20%)       | >0.001|
|           | Normal   | 333 (96.20%)    | 13 (3.80%)        |      |
| Comorbidities | LD     | No              | 358 (95.95%)     | 25 (4.05%)   |
|           |         | Yes             | 8 (72.77%)       | 3 (27.23%) |
| IHD       | No       | 351 (93.90%)    | 23 (6.10%)        | 0.001 |
|           | Yes      | 15 (75.00%)     | 5 (25.00%)        |      |
| CHF       | No       | 337 (93.90%)    | 22 (6.10%)        | 0.015 |
|           | Yes      | 29 (82.90%)     | 6 (17.10%)        |      |
| DM        | No       | 289 (93.20%)    | 21 (6.80%)        | 0.622 |
|           | Yes      | 77 (71.90%)     | 33 (28.10%)       |      |
| HT        | No       | 221 (93.20%)    | 16 (6.80%)        | 0.736 |
|           | Yes      | 145 (92.40%)    | 12 (7.60%)        |      |
| CRF       | No       | 347 (93.50%)    | 25 (6.70%)        | 0.199 |
|           | Yes      | 19 (86.40%)     | 3 (13.60%)        |      |

*Fisher’s Exact Test
LD: Liver disease, IHD: Ischemic heart disease, CHF: Congestive heart failure, DM: Diabetes mellitus, HT: Hypertension, CRF: Chronic renal failure, Sig: asymptotic 2-sided significance between groups

### Table 2. Descriptive statistics for age, vital parameters, laboratory measurements and severity scores in terms of in-hospital mortality for UGIB patients

| Variables | All Patients (n=394) | Survivor (n=356) | Non-survivor (n=38) | p    |
|-----------|----------------------|-----------------|---------------------|------|
| Age, Median (25th-75th) | 68 (54-75) | 67 (53-80.25) | 74 (67.5-84.75) | 0.013 |
| Vital signs and GCS, Median (25th-75th) | | | | |
| SBP (mmHg) | 120 (110-130) | 120 (110-130) | 90 (80-108.75) | <0.001 |
| DBP (mmHg) | 64 (57-70) | 65 (60-72) | 50 (40-65) | <0.001 |
| HR (bpm) | 98 (90-106.25) | 98 (90-105) | 105 (95.25-110) | 0.010 |
| spO2 (%) | 97 (96-98) | 97 (96-98) | 96 (92.50-98) | 0.038 |
| Laboratory measurements, Median (25th-75th) | | | | |
| Hemoglobin (g/dl) | 8.7 (7.60-10.02) | 8.8 (7.8-10.1) | 5.85 (4.72-7.7) | <0.001 |
| Platelet (103/ul) | 212 (153.5-265) | 210 (153.5-262.25) | 237 (146.75-313.5) | 0.634 |
| Urea (mg/dl) | 63 (40.75-96.25) | 59 (59-91) | 104.5 (71.25-177.5) | <0.001 |
| Creatinine (mg/dl) | 0.82 (0.65-1.04) | 0.81 (0.64-1.01) | 0.93 (0.72-2.02) | 0.012 |
| INR | 1.18 (1.08-1.33) | 1.17 (1.07-1.31) | 1.51 (1.22-1.96) | <0.001 |
| Albumin (g/L) | 31 (0.33-37.5) | 31 (28-35) | 26 (21.13-28) | <0.001 |

### Table 3. Predictive performance of AIMS65 score and Shock index in terms of mortality for upper gastrointestinal bleeding

| Variables | Sensitivity(95% CI) | Specificity(95% CI) | PPV (95% CI) | NPV (95% CI) | AUC (95% CI) | YII (95% CI) | Criterion of YII | p* |
|-----------|---------------------|---------------------|--------------|--------------|--------------|--------------|-----------------|----|
| AIMS65 score | 0.1000 (87.7-100) | 64.21 (59.1 - 69.1) | 19.185 (15.7-19.7) | 100 (≥ 0.5) | 0.917 (0.885-0.942) | 0.642 | x2 | <0.001 |
| Shock index | 0.81 (0.75-0.89) | 88.80 (85.4 - 92.1) | 32.8 (25.2 - 41.4) | 97.6 (95.8 - 98.6) | 0.807 (0.764-0.845) | 0.602 | >0.967 | <0.001 |

*In the pairwise comparison of the ROC curves of AIMS65 score and Shock Index, the p value is calculated as 0.0289.
Pp: asymptotic 2-sided significance between groups, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, HR: Heart rate, spO2: Blood oxygen saturation, INR: International normalized ratio, UGIB: Upper gastrointestinal bleeding

### Discussion
Early diagnosis of UGIB patients with a high risk of poor prognosis will reduce morbidity and mortality. Likewise, classifying UGIB patients at a low risk may lead to the safe and early discharge of these patients, resulting in the appropriate use of healthcare resources.

In this study, the performances of SI and AIMS65 scores in predicting mortality in patients with UGIB were examined. Although the results of both prediction models were found to be satisfactory, the AIMS65 score demonstrated the best accuracy at predicting mortality with AUROC [95% CI]: 0.917 [0.885-0.942].

Patients presenting to ED with UGIB have a high risk of morbidity and mortality.

---

AIMS65 score and shock index in patients with acute upper gastrointestinal bleeding
and mortality. In the USA, more than one million patients are admitted annually due to GI bleeding [13]. Numerous risk assessment scores have been developed for these patients, but most of the scores include endoscopic data and do not seem useful for ED [14]. Saltzman et al. created the AIMS65 score with pre-endoscopic data, which was validated using 2 optimal cut-off points in a retrospective cohort of 32,504 patients. This study reported sensitivity and specificity of 0.79 and 0.61, respectively, for predicting mortality [9]. In Yaka et al.’s cohort of 254 patients, the AIMS65 score was successful in predicting mortality with an AUC of 0.81 [15]. In prospective observational study by Chang et al., AIMS65, Glasgow-Blatchford, and Rockall scores were compared, and the AIMS65 score was found to be superior to other scores with an AUC of 0.747 in estimating mortality [16]. In another study comparing AIMS65, Glasgow-Blatchford, and Rockall scores, AIMS65 was found to be the most successful scoring system with an AUC value of 0.91 in mortality prediction [17].

SI has attracted the attention of researchers since the first day it was defined and has been studied in many different diseases such as hypovolemia, sepsis, and myocardial infarction [18-20]. Similarly, there are studies on SI in predicting the prognosis of patients with UGIB. In a study examining the relationship of SI with poor prognosis in patients with UGIB, it was reported that shock index values greater than 0.7 were effective in predicting the need for intensive care, blood transfusion and endoscopic treatment [21]. In another study, it was reported that high SI values were associated with angiographic extravasation in patients with UGIB [22]. In the newly developed scoring system of Horibe et al., SI was used as a variable of the score, and they reported that this score was successful in determining the endoscopic intervention [23]. However, there are also studies reporting that SI is not a useful prediction tool. In the study by Saffouri et al., SI, Glasgow Blatchford, AIMS65, ABC, and admission Rockall scores were compared to predict the prognosis of patients with UGIB. In terms of major transfusion, endotherapy, and 30-day mortality, the SI was found to be unsuccessful compared to other scores. The authors reported that the patients in this study were younger, had less cardiovascular morbidity, and were using less antihypertensive medication. They emphasized that these factors may explain why SI is less useful in predicting the outcome of patients with UGIB [24].

There are some limitations in our study. First, this is a single-center retrospective study conducted on a relatively small population and should be validated in a larger, multi-center cohort. In addition, it should be kept in mind that the presence of underlying comorbidities such as hypertension, diabetes mellitus, or coronary artery disease may suppress the predictive value of SI.

**Conclusions**

In this study, the AIMS65 score was found to be more successful than SI in predicting mortality in UGIB patients. We suggest that the AIMS65 score, which does not require endoscopic data and patients’ comorbidity information and can be easily calculated in emergency departments, should be used to estimate mortality in UGIB patients.

**Scientific Responsibility Statement**

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

**Animal and human rights statement**

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

**Funding:** None

**Conflict of interest**

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

**References**

1. Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010; 152(2):101-13.

2. Jairath V, Martel M, Logan RF, Barkun AN. Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A systematic review of cohort studies. Can J Gastroenterol. 2012; 26(8):537-43.

3. Klein A, Gralnek IM. Acute, nonvariceal upper gastrointestinal bleeding. Curr Opin Crit Care. 2015; 21(2):154-62.

4. Barkun AN, Almodi M, Kuipers EJ, Laine L, Sung J, Tse F, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019; 171(11):805-22.

5. Sung JJ, Chiou PW, Chan FK, Lau JY, Goh KL, Ho LH, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2019; 68(10):1757-68.

6. Saeed ZA, Ramirez FC, Hepps KS, Cole RA, Graham DV. Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc. 1995; 41(6):561-5.

7. Cieniawski D, Kuźniar E, Winiarski M, Matłok M, Kostarczyk W, Pedziwiatr M. Prognostic value of the Rockall score in patients with acute nonvariceal bleeding from the upper gastrointestinal tract. Przegl Lek. 2013; 70(1):1-5.

8. Wang CY, Qin J, Wang J, Sun CY, Cao T, Zhu DD. Rockall score in predicting outcomes of elderly patients with acute upper gastrointestinal bleeding. World J Gastroenterol. 2013; 19(22):3466-72.

9. Saltzman JR, Tabak YP, Hyett BH, Sun X, Travis AC, Johannes RS. A simple risk score accurately predicts in-hospital mortality, length of stay, and cost in acute upper GI bleeding. Gastrointest Endosc. 2011; 74(6):1215-24.

10. Birkhahn RH, Gaeta TJ, Terry D, Bove JJ, Tloczkowski J. Shock index in diagnosing early acute hypovolemia. Am J Emerg Med. 2005; 23(3):323-6.

11. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44(3):837-45.

12. Greiner M, Pfeffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med. 2000; 45(1-2):23-41.

13. Goralnick E, Meguerdichian DA. Gastrointestinal bleeding. Rosen's Emergency Medicine: Concepts and Clinical Practice. 8th ed. Philadelphia, PA: Elsevier Saunders, 2014.

14. Ramaekers R, Mukarram M, Smith CA, Thiruganasambandamoorthy V. The predictive value of preendoscopic risk scores to predict adverse outcomes in emergency department patients with upper gastrointestinal bleeding: a systematic review. Acad Emerg Med. 2016; 23(3):128-127.

15. Yaka E, Yilmaz S, Özgür Doğan N, Pekdemir M. Comparison of the Glasgow-Blatchford and AIMS 65 Scoring Systems for Risk Stratification in Upper Gastrointestinal Bleeding in the Emergency Department. Acad Emerg Med. 2015; 22(1):22-30.

16. Chang A, Ouejarajphant C, Akarapolita K, Rattanasupa A, Prachayakul V. Prospective comparison of the AIMS65 score, Glasgow-Blatchford Score, and Rockall Score for predicting clinical outcomes in patients with variceal and nonvariceal upper gastrointestinal bleeding. Clinical Endoscopy. 2021; 54(2):211-217.

17. Gu L, Xu F, Yuan J. Comparison of AIMS65, Glasgow-Blatchford and Rockall scoring approaches in predicting the risk of in-hospital death among emergency hospitalized patients with upper gastrointestinal bleeding: a retrospective observational study in Nanjing, China. BMC Gastroenterol. 2018; 18(1):98.

18. Sankaran P, Kamath AV, Tariq SM, Ruffell H, Smith AC, Prentice P, et al. Are shock index and adjusted shock index useful in predicting mortality and length of stay in community-acquired pneumonia? European Journal of Internal Medicine. 2011; 22(3):282-5.

19. El Ayadi AM, Nathan HL, Seed PT, Buttrick EA, Hezelgrave NL, Shennan AH, et al. Vital sign prediction of adverse maternal outcomes in women with hypovolemic shock: the role of shock index. PloS One. 2016; 11(2):e0148729.
20. Reinstadler SJ, Fuernau G, Eitel C, de Waha S, Desch S, Metzler B, et al. Shock index as a predictor of myocardial damage and clinical outcome in ST-elevation myocardial infarction. Circulation Journal. 2016; 80(4):924-30.
21. Rassameehiran S, Teerakanok J, Suchartlikitwong S, Nugent K. Utility of the Shock Index for Risk Stratification in Patients with Acute Upper Gastrointestinal Bleeding. South Med J. 2017; 110(11):738-43.
22. Nakasone Y, Ikeda O, Yamashita Y, Kudoh K, Shigematsu Y, Harada K. Shock index correlates with extravasation on angiographs of gastrointestinal hemorrhage: a logistics regression analysis. Cardiovasc Intervent Radiol. 2007; 30(5):861-5.
23. Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, et al. A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: a prospective cohort study. Digestive and Liver Disease. 2016; 48(10):1180-6.
24. Saffouri E, Blackwell C, Laursen SB, Laine L, Dalton HR, Ngu J, et al. The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2020; 51(2):253-60.

How to cite this article:
Fatih Doğanay, Erdal Yılmaz. AIMS65 score and shock index in predicting mortality in patients with acute upper gastrointestinal bleeding. Ann Clin Anal Med 2021;12(Suppl 4): S483-487